Scholarlink

<p>Laryngopharyngeal reflux (LPR) is a general term for the reflux of fluid from the stomach into the upper airways, including the laryngopharynx, oropharynx, and even the nasopharynx. It causes a number of symptoms and is an inflammatory response of the upper airways. The pathophysiology and treatment of LPR remain controversial, and there is no gold standard for either. Unlike PPIs, Vonoprazan is a potassium-competitive acid blocker (P-CAB) that is first in class and does not require acid-dependent activation. This retrospective study conducted in the patients with LPR presented to the ENT OPD from January 2025 to June 2025 at tertiary care teaching hospital in North India. Total 60 patients which were divided into two groups and were evaluated on basis of reflux symptom index (RSI) and reflux finding score (RFS). It has been found that there is improvement in RFS and RSI scores: After 1week, RFS and RSI scores within each group, improved significantly with Vonoprazan comparatively to Esomeprazole therapy with significant p value &lt; 0.00001. Many of the unmet requirements of PPI treatment for GERD may be addressed by P-CABs. Vonoprazan demonstrated greater short-term improvement in both the symptom index (RSI) and sign score (RFS) in patients with LPRD. Further studies with larger cohorts and longer follow-up are required to establish its long-term efficacy and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vonoprazan: A Boon in the Treatment of Laryngopharyngeal Reflux

  • 期刊论文

  • 发表日期：

    2025年10月14日

查看全文
  • Kanchan Garg,
  • Puneet Shukla,
  • Kumar Shubhanshu,
  • Prankur Awasthi

摘要

Laryngopharyngeal reflux (LPR) is a general term for the reflux of fluid from the stomach into the upper airways, including the laryngopharynx, oropharynx, and even the nasopharynx. It causes a number of symptoms and is an inflammatory response of the upper airways. The pathophysiology and treatment of LPR remain controversial, and there is no gold standard for either. Unlike PPIs, Vonoprazan is a potassium-competitive acid blocker (P-CAB) that is first in class and does not require acid-dependent activation. This retrospective study conducted in the patients with LPR presented to the ENT OPD from January 2025 to June 2025 at tertiary care teaching hospital in North India. Total 60 patients which were divided into two groups and were evaluated on basis of reflux symptom index (RSI) and reflux finding score (RFS). It has been found that there is improvement in RFS and RSI scores: After 1week, RFS and RSI scores within each group, improved significantly with Vonoprazan comparatively to Esomeprazole therapy with significant p value < 0.00001. Many of the unmet requirements of PPI treatment for GERD may be addressed by P-CABs. Vonoprazan demonstrated greater short-term improvement in both the symptom index (RSI) and sign score (RFS) in patients with LPRD. Further studies with larger cohorts and longer follow-up are required to establish its long-term efficacy and safety.